These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 14764054)

  • 1. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.
    Al-Hussaini M; Stockman A; Foster H; McCluggage WG
    Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
    McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
    Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of WT1, B-cell lymphoma 2, Ki-67 (Mib1), and Her2/Neu as diagnostic and prognostic immunomarkers in ovarian serous and endometroid carcinoma.
    Mondal SK; Basak B; Bhattacharya S; Panda UK
    J Cancer Res Ther; 2021; 17(1):164-169. PubMed ID: 33723149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site.
    Celik B; Bulut T; Yalcin AD
    Pathol Oncol Res; 2020 Apr; 26(2):1145-1151. PubMed ID: 31165997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS-mutated Uterine Endometrioid Carcinoma With Extensive Surface Changes Resulting in Striking Morphologic Mimicry of an Ovarian Serous Borderline Tumor.
    Kir G; Olgun ZC; Gunel H; Ozen F; McCluggage WG
    Int J Gynecol Pathol; 2020 Nov; 39(6):573-577. PubMed ID: 31855953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
    Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
    Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences.
    Soslow RA; Slomovitz BM; Saqi A; Baergen RN; Caputo TA
    Gynecol Oncol; 2000 Dec; 79(3):430-7. PubMed ID: 11104615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.
    Egan JA; Ionescu MC; Eapen E; Jones JG; Marshall DS
    Int J Gynecol Pathol; 2004 Apr; 23(2):119-22. PubMed ID: 15084839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometrioid adenocarcinoma of the ovary mimicking serous borderline tumor: report of a series of cases.
    Mansor S; McCluggage WG
    Int J Gynecol Pathol; 2014 Sep; 33(5):470-6. PubMed ID: 25083962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WT-1 in ovarian and endometrioid serous carcinoma: a meta-analysis.
    Heatley MK
    Histopathology; 2005 Apr; 46(4):468. PubMed ID: 15810962
    [No Abstract]   [Full Text] [Related]  

  • 13. WT1 Positive Ovarian Endometrioid Tumors: Observations From Consult Cases and Strategies for Distinguishing From Serous Neoplasms.
    Rajendran S; McCluggage WG
    Int J Gynecol Pathol; 2022 Mar; 41(2):191-202. PubMed ID: 33782345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
    Li C; Zota V; Woda BA; Rock KL; Fraire AE; Jiang Z; Lu D; Xu B; Dresser K; Lutman CV; Fischer AH
    Mod Pathol; 2007 Dec; 20(12):1263-8. PubMed ID: 17885673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.
    Zhao C; Bratthauer GL; Barner R; Vang R
    Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
    Morency E; Leitao MM; Soslow RA
    Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
    Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
    Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesonephric-like Differentiation of Ovarian Endometrioid and High-grade Serous Carcinomas: Clinicopathological and Molecular Characteristics Distinct from Those of Mesonephric-like Adenocarcinoma.
    Choi KH; Kim H; Bae GE; Lee SH; Woo HY; Kim HS
    Anticancer Res; 2021 Sep; 41(9):4587-4601. PubMed ID: 34475087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.